SOT-102

N/A

Report date: 2024/02/05 14:07:42

Base Information

Drug NameSOT-102

Drug Alias NameSOT-102SOT102SO-N102

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > Non-cleavable peptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PNU-159682 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-CLDN18

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsPancreatic NeoplasmsStomach Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBelgiumUnited States +[5]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesSotio Biotech AG

China Registration ClassN/A

Develop Information

Active CompaniesSotio Biotech AG

Inactive CompaniesSOTIO Biotech a s

Active IndicationsPancreatic NeoplasmsStomach Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A